Mean fasting plasma glucose levels were 9

Mean fasting plasma glucose levels were 9.23 in DM patients, and 5.20 in non-DM patients (= 16.849, 0.001). significant (= 0.041), but recurrence-free survival rates were not (= 0.096). By stratified analysis, the overall survival rates in DM patients for age 50 years (= 0.002), the presence of vascular invasion (= 0.096), tumors 3 cm (= 0.047), two to three tumor nodules (= 0.007), Child-Pugh grade B (= 0.018), and pre-LT alanine cIAP1 ligand 1 aminotransferase levels between 40 and 80 IU/L (= 0.017) were significantly lower than in non-DM patients. Additionally, serum -fetoprotein level 2000 ng/mL (= 0.052) was associated with a significant survival difference trend between DM and non-DM patients. Multivariate analysis showed that the presence of DM ( 0.001, HR = 1.591; 95%CI: 1.239-2.041) was an independent predictor associated with poor survival after LT. CONCLUSION HBV-related HCC patients with DM have decreased long-term overall survival and poor LT outcomes. Prevention strategies for HCC patients with DM are recommended. (%) = 295)Non-diabetic (= 1336)Valuedfvalueof 0.05 was considered statistically significant. RESULTS Baseline characteristic comparisons between HBV-HCC patients with or without DM The mean ages in patients with or without DM were 54.1 or 50.8, respectively (= 6.597, 0.001). Mean cIAP1 ligand 1 patient BMI with or without DM was 24.2 for both (= 0.036, = 0.971). Mean fasting plasma glucose levels were 9.23 in DM patients, and 5.20 in non-DM patients (= 16.849, 0.001). The mean TC level (= 2.342, = 0.019) and CH level (= 1.106, = 0.269) were 1.12 or 4.46 in DM patients and 0.92 or 3.82 in non-DM patients, respectively. In the current study, patients with DM exhibited a higher proportion of individuals with age 50-years-old (67.5% 51.9%, 2 = 23.690, 0.001), Child-Pugh grade B (35.3% 29.6%, 2 = 13.456, = 0.002) and C (22.4% 16.8%, 2 = 13.456, = 0.002), MELD scores 15 (35.3% 26.0%, 2 = 14.184, = 0.001), BMI of 24-28 (28.5% Mouse monoclonal antibody to Keratin 7. The protein encoded by this gene is a member of the keratin gene family. The type IIcytokeratins consist of basic or neutral proteins which are arranged in pairs of heterotypic keratinchains coexpressed during differentiation of simple and stratified epithelial tissues. This type IIcytokeratin is specifically expressed in the simple epithelia lining the cavities of the internalorgans and in the gland ducts and blood vessels. The genes encoding the type II cytokeratinsare clustered in a region of chromosome 12q12-q13. Alternative splicing may result in severaltranscript variants; however, not all variants have been fully described 22.1%, 2 = 7.937, = 0.047), TC 1.7 mmol/L (15.3% 6.8%, 2 = 22.536, 0.001) and HBV DNA 103 IU/mL (64.7% 56.9%, 2 = 6.140, = 0.013), when compared with non-DM patients (Table ?(Table11). Analysis cIAP1 ligand 1 of DM and non-DM patients showed significant differences in age ( 0.001), MELD scores (= 0.001), Child-Pugh grade (= 0.002), BMI (= 0.047), TC levels ( 0.001) and HBV DNA (= 0.013; Table ?Table1).1). No significant differences were observed between patients with and without DM for other factors analyzed (Table ?(Table11). Overall survival and tumor recurrence comparisons by univariate analysis between HBV-HCC patients with or without DM Complete follow-up monitoring of the 1631 HBV-associated HCC patients who underwent LT was conducted. The median survival time was 62.0 39.1 mo (0 to 152 mo) in DM patients and 67.0 38.9 mo (0 to 165 mo) in non-DM patients. Univariate analysis of 1631 patients showed that 1-, 3- and 5-year overall survival rates post-LT were 79%, 73% and 71% in DM patients, respectively, and 84%, 78% and 76% in non-DM patients, respectively. Overall survival rates post-LT were significantly different between the HCC patients with DM and those without DM (= 0.041; Physique ?Figure1A1A). Open in a separate window Physique 1 Overall (A) and recurrence-free (B) survival rates of diabetes mellitus and non-diabetes mellitus patients with hepatocellular carcinoma. DM: Diabetes mellitus. The median tumor recurrence-free survival time was 55.0 40.9 mo in DM patients and 62.0 41.3 mo (0 to 165 mo) in non-DM patients. Univariate analysis of.